Karyopharm Therapeutics Inc. (KPTI) Key Statistics & Metrics

Karyopharm Therapeutics Inc. (KPTI) has an ST Score of 48.2 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate KPTI a Buy, with a price target of $9.50 (+2549.2% vs the current price). Our ST Score grades it C+ (48.2/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C, Profitability B, Financial Strength C-, Momentum D+, Growth A, Forecast B+.

Karyopharm Therapeutics Inc. (KPTI) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Karyopharm Therapeutics Inc. (KPTI) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Karyopharm Therapeutics Inc. (KPTI) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Karyopharm Therapeutics Inc. (KPTI) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Karyopharm Therapeutics Inc. (KPTI) is $9.50 from 20 analysts, which is +2549.2% versus the recent price of $0.36.

Karyopharm Therapeutics Inc. (KPTI) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.